NVOHNovo Nordisk A/S (B Shares) ADRhedged
Seeks to provide investment results that correspond generally to the total return of the ordinary shares of Novo Nordisk A/S (B Shares) in its local market.
By ADRH · Launched 2025
Annual Cost
0.19%
#870 of 6,040 · low cost
Fund Size
$4M
#5,402 of 6,040 · small
Return (1Y)
-17.4%
Track Record
1 year
#4,000 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$8,108-18.9%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityStrategy
Single stock
Holdings
By weightConcentration
single-stock exposure — holdings shown are derivatives collateral, not the fund's position
Novo Nordisk A/S
93.8%
DREYFUS TRSRY SECURITIES
3.8%
CANADIAN IMPERIAL BANK OF COMMERCE
-0.4%
Asset allocation
Stocks
97.7%
Cash
2.4%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
44.7%High
Year-on-year price swings
Max drawdown
-61.6%Severe
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks to provide investment results that correspond generally to the total return of the ordinary shares of Novo Nordisk A/S (B Shares) in its local market.
- Strategy
- Invests at least 95% of net assets in ADRs of Novo Nordisk A/S (B Shares) and uses a currency swap to hedge against fluctuations in the exchange rate between the U.S. dollar and the Danish krone. The Series does not seek to replicate the performance of a specified index and is non-diversified.
- Inception date
- January 6, 2025
- Fund family
- ADRH
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save NVOH to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18